Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response

Thrombosis Research

Volumn 123, Issue 4, 2009, Pages 597-603

  Cuisset, Thomas ^a   Frere, Corinne ^a   Quilici, Jacques ^a   Morange, Pierre Emmanuel ^a   Camoin, Laurence ^b   Bali, Laurent ^a   Lambert, Marc ^a   Juhan Vague, Irène ^a   Alessi, Marie Christine ^a   Bonnet, Jean Louis ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; ARACHIDONIC ACID; ASPIRIN; BODY MASS INDEX; CELL ADHESION MOLECULES; DIABETES COMPLICATIONS; DRUG RESISTANCE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 58949088841     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.04.003     Document Type: Article

References (29)

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
2. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
3. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 14 (Apr 10 2007) 1505-1516
4. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
5. Cuisset T., Frere C., Quilici J., Barbou F., Morange P.E., Hovasse T., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
6. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 9 (2006) 1742-1750
7. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., et al. Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
8. Sanderson S., Emery J., Baglin T., and Kinmonth A.L. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142 (2005) 370-380
9. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
10. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
11. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
12. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33 21
13. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., et al. Benefit of a 600 mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST elevation Acute Coronary Syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
14. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., and Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3 (2005) 85-92
15. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., Barrera Ramírez C., Sabaté M., Fernandez C., et al. Platelet Aggregation According to Body Mass Index in Patients Undergoing Coronary Stenting: Should Clopidogrel Loading-Dose Be Weight Adjusted?. J Invasive Cardiol 16 (2004) 169-174
16. Scherrer U., Nussberger J., Torriani S., Waeber B., Darioli R., Hofstetter J.R., et al. Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytostolic platelet calcium. Circulation 83 (1991) 552-558
17. Kotlyar M., and Carson S.W. Effects of obesity on the cytochrome P450 enzyme system. Int J Pharmacol Ther 37 (1999) 8-19
18. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Jimenez-Quevedo P., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
19. Angiolillo D.J., Bernardo E., Ramírez C., Costa M.A., Sabaté M., Jimenez-Quevedo P., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
20. Ferreira I.A., Mocking A.I., Feijge M.A., Gorter G., van Haeften T.W., Heemskerk J.W., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26 (2006) 417-422
21. Ferroni P., Basili S., Falco A., and Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2 (2004) 1282-1291
22. Schühlen H., Kastrati A., Dirschinger J., Hausleiter J., Elezi S., Wehinger A., et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 98 (1998) 104-111
23. Silva J.A., Ramee S.R., White C.J., Collins T.J., Jenkins J.S., Nunez E., et al. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 138 (1999) 446-455
24. Samara W.M., Bliden K.P., Tantry U.S., and Gurbel P.A. The difference between clopidogrel responsiveness and post treatment platelet reactivity. Thromb Res 115 (2005) 89-94
25. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
26. von Beckerath N., Taubert D., Pogatsa-Murray G., Schömig E., Kastrati A., and Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
27. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 115 (2007) 708-716
28. Jernberg T., Payne C.D., Winters K.J., Darstein C., Brandt J.T., Jakubowski J.A., et al. Prasugrel achieves greater inhibition of platelet agregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173
29. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med (Nov 4 2007) [Electronic publication ahead of print]